Literature DB >> 9556553

Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin.

S Kishida1, H Yamamoto, S Ikeda, M Kishida, I Sakamoto, S Koyama, A Kikuchi.   

Abstract

The regulators of G protein signaling (RGS) domain of Axin, a negative regulator of the Wnt signaling pathway, made a complex with full-length adenomatous polyposis coli (APC) in COS, 293, and L cells but not with truncated APC in SW480 or DLD-1 cells. The RGS domain directly interacted with the region containing the 20-amino acid repeats but not with that containing the 15-amino acid repeats of APC, although both regions are known to bind to beta-catenin. In the region containing seven 20-amino acid repeats, the region containing the latter five repeats bound to the RGS domain of Axin. Axin and beta-catenin simultaneously interacted with APC. Furthermore, Axin stimulated the degradation of beta-catenin in COS cells. Taken together with our recent observations that Axin directly interacts with glycogen synthase kinase-3beta (GSK-3beta) and beta-catenin and that it promotes GSK-3beta-dependent phosphorylation of beta-catenin, these results suggest that Axin, APC, GSK-3beta, and beta-catenin make a tetrameric complex, resulting in the regulation of the stabilization of beta-catenin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9556553     DOI: 10.1074/jbc.273.18.10823

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  153 in total

1.  Membrane-anchored plakoglobins have multiple mechanisms of action in Wnt signaling.

Authors:  M W Klymkowsky; B O Williams; G D Barish; H E Varmus; Y E Vourgourakis
Journal:  Mol Biol Cell       Date:  1999-10       Impact factor: 4.138

2.  Cloning and mitochondrial localization of full-length D-AKAP2, a protein kinase A anchoring protein.

Authors:  L Wang; R K Sunahara; A Krumins; G Perkins; M L Crochiere; M Mackey; S Bell; M H Ellisman; S S Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

3.  Inhibition of the Wnt signaling pathway by Idax, a novel Dvl-binding protein.

Authors:  S Hino; S Kishida; T Michiue; A Fukui; I Sakamoto; S Takada; M Asashima; A Kikuchi
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

Review 4.  T-cell factors: turn-ons and turn-offs.

Authors:  Adam Hurlstone; Hans Clevers
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

5.  An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin.

Authors:  M Kitagawa; S Hatakeyama; M Shirane; M Matsumoto; N Ishida; K Hattori; I Nakamichi; A Kikuchi; K Nakayama; K Nakayama
Journal:  EMBO J       Date:  1999-05-04       Impact factor: 11.598

Review 6.  APC as a checkpoint gene: the beginning or the end?

Authors:  Vincent W Yang
Journal:  Gastroenterology       Date:  2002-09       Impact factor: 22.682

7.  Calpain as an effector of the Gq signaling pathway for inhibition of Wnt/beta -catenin-regulated cell proliferation.

Authors:  Guangnan Li; Ravi Iyengar
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-18       Impact factor: 11.205

8.  MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis.

Authors:  Junchao Cai; Hongyu Guan; Lishan Fang; Yi Yang; Xun Zhu; Jie Yuan; Jueheng Wu; Mengfeng Li
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

9.  Genetic and pathologic evolution of early secondary gliosarcoma.

Authors:  Kari-Elise T Codispoti; Stacy Mosier; Robert Ramsey; Ming-Tseh Lin; Fausto J Rodriguez
Journal:  Brain Tumor Pathol       Date:  2013-01-17       Impact factor: 3.298

10.  c-Jun N-terminal kinase 1 interacts with and negatively regulates Wnt/beta-catenin signaling through GSK3beta pathway.

Authors:  Dong Hu; Wenfeng Fang; Anjia Han; Lindsay Gallagher; Roger J Davis; Bin Xiong; Wancai Yang
Journal:  Carcinogenesis       Date:  2008-10-24       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.